Reviewing Albany Molecular Research (AMRI) and ACADIA Pharmaceuticals (ACAD)

ACADIA Pharmaceuticals (NASDAQ: ACAD) and Albany Molecular Research (NASDAQ:AMRI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for ACADIA Pharmaceuticals and Albany Molecular Research, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ACADIA Pharmaceuticals 0 2 10 0 2.83
Albany Molecular Research 0 4 0 0 2.00

ACADIA Pharmaceuticals currently has a consensus target price of $49.42, suggesting a potential upside of 64.89%. Albany Molecular Research has a consensus target price of $18.00, suggesting a potential downside of 17.20%. Given ACADIA Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Albany Molecular Research.

Earnings & Valuation

This table compares ACADIA Pharmaceuticals and Albany Molecular Research’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ACADIA Pharmaceuticals $17.33 million 214.81 -$271.39 million ($2.45) -12.23
Albany Molecular Research N/A N/A N/A ($1.43) -15.20

Albany Molecular Research has lower revenue, but higher earnings than ACADIA Pharmaceuticals. Albany Molecular Research is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

ACADIA Pharmaceuticals has a beta of 3.8, suggesting that its stock price is 280% more volatile than the S&P 500. Comparatively, Albany Molecular Research has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.

Institutional and Insider Ownership

94.0% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.1% of Albany Molecular Research shares are owned by institutional investors. 22.3% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 14.5% of Albany Molecular Research shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares ACADIA Pharmaceuticals and Albany Molecular Research’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals -320.71% -67.68% -61.88%
Albany Molecular Research -5.93% -13.39% -3.42%

Summary

ACADIA Pharmaceuticals beats Albany Molecular Research on 7 of the 11 factors compared between the two stocks.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer’s disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.

About Albany Molecular Research

Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply